| Literature DB >> 24954006 |
Melinda M Mulvihill1, Daniel I Benjamin1, Xiaodan Ji2, Erwan Le Scolan2, Sharon M Louie1, Alice Shieh1, McKenna Green1, Tara Narasimhalu1, Patrick J Morris1, Kunxin Luo2, Daniel K Nomura3.
Abstract
Many studies have identified metabolic pathways that underlie cellular transformation, but the metabolic drivers of cancer progression remain less well understood. The Hippo transducer pathway has been shown to confer malignant traits on breast cancer cells. In this study, we used metabolic mapping platforms to identify biochemical drivers of cellular transformation and malignant progression driven through RAS and the Hippo pathway in breast cancer and identified platelet-activating factor acetylhydrolase 1B3 (PAFAH1B3) as a key metabolic driver of breast cancer pathogenicity that is upregulated in primary human breast tumors and correlated with poor prognosis. Metabolomic profiling suggests that PAFAH1B3 inactivation attenuates cancer pathogenicity through enhancing tumor-suppressing signaling lipids. Our studies provide a map of altered metabolism that underlies breast cancer progression and put forth PAFAH1B3 as a critical metabolic node in breast cancer.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24954006 PMCID： PMC4119799 DOI： 10.1016/j.chembiol.2014.05.008
Source DB: PubMed Journal: Chem Biol ISSN： 1074-5521